Uncategorized

Replicor updates clinical efficacy results in patients with chronic hepatitis B with short term exposure to immunotherapy in combination with REP 2139-ca. February 27th, 2013 – Tokyo, Japan. February 27th, 2013 – Replicor is currently undertaking a proof of concept trial in patients with chronic hepatitis B (HBV) undergoing treatment with its nucleic acid polymer (NAP)…

10 November 2012, Boston, U.S.A. and Nanjing, China. Friday , November 9th, 2012 – Replicor is currently undertaking a proof of concept trial in patients with chronic hepatitis B (HBV) undergoing treatment with its nucleic acid polymer (NAP) REP 2139 in combination with Zadaxin™ or Pegasys™. The hepatitis B surface antigen protein (HBsAg) is produced in…

25 September 2012, Oxford, England. September 25, 2012 – Replicor is currently undertaking a proof of concept trial in patients with chronic hepatitis B (HBV) undergoing treatment with its nucleic acid polymer (NAP) REP 2139 in combination with Zadaxin™ or Pegasys™. The hepatitis B surface antigen protein (HBsAg) is produced in large excess by the HBV…

22-25 June 2012, Shanghai International Convention Center, Shanghai, China. June 22nd, 2012 – Replicor will disclose updated interim results and metadata analysis of antiviral responses in patients with chronic hepatitis B who are enrolled in its proof of concept clinical trials of REP 2055 and REP 2139 for the treatment of chronic hepatitis B at the…

15-19 February 2012, Taiwan International Convention Center, Taipei, Taiwan. February 17th, 2012 – Replicor will disclose updated interim results from its proof of concept clinical trial of its second clinical candidate, REP 2139 for the treatment of chronic hepatitis B at the 22nd Conference of the Asian Pacific Association for the Study of the Liver…

December 4-8, 2011, Grand Hyatt Kauai, Koloa, Hawaii November 25, 2011 – Replicor will disclose new mechanism of action data and updated interim results from its two proof of concept clinical trials with REP 2055 and REP 2139 at the 2011 HEPDART meeting to be held from December 4th-8th, 2011. This exclusive meeting is only…

Nov 4-8, 2011, Moscone Convention Center West, San Francisco USA Oct 27, 2011 – Replicor will disclose updated interim results from its proof of concept clinical trial at the 62nd annual meeting of the American Association for the Study of Liver Diseases (AASLD 2011) to be held Nov 4-8, 2011. This is the largest annual…

March 30-April 3, 2011, Internationales Congress Centrum (ICC) Berlin, Germany March 30, 2011 – Replicor will disclose updated interim results from its proof of concept clinical trial at the 46th meeting of the European Association for the Study of the Liver (EASL 2011) currently being held from March 30 – April 3. This is the…

17-20 February 2011, QSNCC, Bangkok Thailand February 17, 2011 – Replicor will disclose updated interim results from its proof of concept clinical trial at the 21st Conference of the Asian Pacific Association for the Study of the Liver (APASL 2011) currently being held from 17-20th of February. This is the largest annual meeting in South…

October 28, 2010 – Replicor will disclose updated interim results from its proof of concept clinical trial at the 61st annual meeting of the American Association for the Study of Liver Disease (AASLD) APASL in Boston, U.S.A. (currently being held from Oct 28 – Nov 2). This is the largest annual meeting dedicated to treatment…